M. Andrieux, A. Mouly-badina, L. Clerget, M. Schweitzer, A. Scarna et al., Dopaminergic transmission in STOP null mice, J Neurochem, vol.94, pp.63-73, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00380189

L. Camargo, Q. Wang, and N. Brandon, What can we Learn from the Disrupted in Schizophrenia 1 Interactome: Lessons for Target Identification and Disease Biology?, Novartis Found Symp, vol.289238, pp.208-224, 2008.
DOI : 10.1002/9780470751251.ch17

S. Chiba, R. Hashimoto, S. Hattori, M. Yohda, B. Lipska et al., Effect of antipsychotic drugson DISC1 and dysbindin expression in mouse frontal cortex and hippocampus, J Neural Transm, 2006.

S. Clapcote, T. Lipina, J. Millar, S. Mackie, S. Christie et al., Behavioral Phenotypes of Disc1 Missense Mutations in Mice, Neuron, vol.54, issue.3, pp.387-402, 2007.
DOI : 10.1016/j.neuron.2007.04.015

J. Coyle and G. Tsai, NMDA Receptor Function, Neuroplasticity, and the Pathophysiology of Schizophrenia, Int Rev Neurobiol, vol.59, pp.491-515, 2004.
DOI : 10.1016/S0074-7742(04)59019-0

E. Denarier, M. Aguezzoul, C. Jolly, . Vourc-h-'c, A. Roure et al., Genomic Structure and Chromosomal Mapping of the Mouse STOP Gene (Mtap6), Biochemical and Biophysical Research Communications, vol.243, issue.3, pp.791-797, 1998.
DOI : 10.1006/bbrc.1998.8179

G. Duncan, S. Zorn, and J. Lieberman, Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia, Molecular Psychiatry, vol.4, issue.5, pp.418-446, 1999.
DOI : 10.1038/sj.mp.4000581

S. Eastwood, L. Lyon, L. George, A. Andrieux, D. Job et al., Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice, Journal of Psychopharmacology, vol.105, issue.6, pp.635-679, 2007.
DOI : 10.1177/0269881106068825
URL : https://hal.archives-ouvertes.fr/inserm-00380032

B. Ellenbroek and A. Cools, Animal models with construct validity for schizophrenia, Behavioural Pharmacology, vol.1, issue.6, pp.469-490, 1990.
DOI : 10.1097/00008877-199000160-00001

L. Ereshefsky, T. Tran-johnson, and M. Watanabe, Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics, Clin Pharm, vol.9, pp.682-707, 1990.

R. Fradley, . Meara-'gf, R. Newman, A. Andrieux, D. Job et al., STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating, Behavioural Brain Research, vol.163, issue.2, pp.257-64, 2005.
DOI : 10.1016/j.bbr.2005.05.012
URL : https://hal.archives-ouvertes.fr/inserm-00380197

W. Frankle, J. Lerma, and M. Laruelle, The Synaptic Hypothesis of Schizophrenia, Neuron, vol.39, issue.2, pp.205-221, 2003.
DOI : 10.1016/S0896-6273(03)00423-9

T. Hikida, H. Jaaro-peled, S. Seshadri, K. Oishi, C. Hookway et al., Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans, Proceedings of the National Academy of Sciences, vol.104, issue.36, 2007.
DOI : 10.1073/pnas.0704774104
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1964873

K. Ishizuka, M. Paek, A. Kamiya, and A. Sawa, A Review of Disrupted-in-Schizophrenia-1 (disc1): Neurodevelopment, Cognition, and Mental Conditions, Biological Psychiatry, vol.59, issue.12, pp.1189-97, 2006.
DOI : 10.1016/j.biopsych.2006.03.065

S. Leucht, C. Corves, D. Arbter, R. Engel, C. Li et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009.
DOI : 10.1016/S0140-6736(08)61764-X
URL : http://mediatum.ub.tum.de/doc/824604/document.pdf

M. Tsuang, D. Malaspina, J. Harkavy-friedman, D. Svrakic, A. Bassett et al., Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia, Am J Hum Genet, vol.73, pp.34-48, 2003.

S. Mackie, J. Millar, and D. Porteous, Role of DISC1 in neural development and schizophrenia, Current Opinion in Neurobiology, vol.17, issue.1, pp.95-102, 2007.
DOI : 10.1016/j.conb.2007.01.007

D. Martins-de-souza, W. Gattaz, A. Schmitt, C. Rewerts, G. Maccarrone et al., Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia, European Archives of Psychiatry and Clinical Neuroscience, vol.107, issue.5, pp.151-63, 2009.
DOI : 10.1007/s00406-008-0847-2

S. Matsuzaki and M. Tohyama, Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1), Neurochemistry International, vol.51, issue.2-4, pp.165-72, 2007.
DOI : 10.1016/j.neuint.2007.06.018

H. Meltzer, What's atypical about atypical antipsychotic drugs?, Current Opinion in Pharmacology, vol.4, issue.1, pp.53-60, 2004.
DOI : 10.1016/j.coph.2003.09.010

K. Miczek and H. De-wit, Challenges for translational psychopharmacology research???some basic principles, Psychopharmacology, vol.21, issue.3, pp.291-301, 2008.
DOI : 10.1007/s00213-008-1198-4

M. Millan, A. Dekeyne, M. Papp, L. Rochelle, C. Macsweeny et al., S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine, J Pharmacol Exp Ther, vol.298, pp.581-91, 2001.

K. Mirnics, F. Middleton, D. Lewis, and P. Levitt, Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse, Trends in Neurosciences, vol.24, issue.8, 2001.
DOI : 10.1016/S0166-2236(00)01862-2

K. Mueser and S. Mcgurk, Schizophrenia, The Lancet, vol.363, issue.9426, pp.2063-72, 2004.
DOI : 10.1016/S0140-6736(04)16458-1

L. Nicolas, Y. Kolb, and E. Prinssen, A combined marble burying???locomotor activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants, European Journal of Pharmacology, vol.547, issue.1-3, pp.106-121, 2006.
DOI : 10.1016/j.ejphar.2006.07.015

Y. Noda, T. Mamiya, H. Furukawa, and T. Nabeshima, Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice, European Journal of Pharmacology, vol.324, issue.2-3, 1997.
DOI : 10.1016/S0014-2999(97)00067-8

Y. Noda, K. Yamada, H. Furukawa, and T. Nabeshima, Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia, British Journal of Pharmacology, vol.9, issue.Suppl. 5, pp.2531-2538, 1995.
DOI : 10.1111/j.1476-5381.1995.tb15106.x

M. Owen, N. Craddock, . Donovan, and . Mc, Schizophrenia: genes at last?, Trends in Genetics, vol.21, issue.9, pp.518-543, 2005.
DOI : 10.1016/j.tig.2005.06.011

M. Owen, . Donovan-'mc, and P. Harrison, Schizophrenia: a genetic disorder of the synapse?, BMJ, vol.330, issue.7484, pp.158-167, 2005.
DOI : 10.1136/bmj.330.7484.158

S. Patil, L. Zhang, F. Martenyi, S. Lowe, K. Jackson et al., Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial, Nature Medicine, vol.43, issue.9, pp.1102-1109, 2007.
DOI : 10.1038/nm1632

J. Peuskens, C. Demily, and T. F. , Treatment of cognitive dysfunction in schizophrenia, Clinical Therapeutics, vol.27, pp.25-37, 2005.
DOI : 10.1016/j.clinthera.2005.07.015

R. Porsolt, A. G. Blavet, N. Jalfre, and M. , Behavioural despair in rats: A new model sensitive to antidepressant treatments, European Journal of Pharmacology, vol.47, issue.4, pp.379-91, 1978.
DOI : 10.1016/0014-2999(78)90118-8

R. Porsolt, A. Bertin, and M. Jalfre, Behavioral despair in mice: a primary screening test for antidepressants, Arch Int Pharmacodyn Ther, vol.229, pp.327-363, 1977.

K. Powell, S. Hori, R. Leslie, A. Andrieux, H. Schellinck et al., Cognitive impairments in the STOP null mouse model of schizophrenia., Behavioral Neuroscience, vol.121, issue.5, pp.826-861, 2007.
DOI : 10.1037/0735-7044.121.5.826
URL : https://hal.archives-ouvertes.fr/inserm-00380034

M. Sakaguchi, M. Koseki, M. Wakamatsu, and E. Matsumura, Effects of systemic administration of ??-casomorphin-5 on learning and memory in mice, European Journal of Pharmacology, vol.530, issue.1-2, pp.81-88, 2006.
DOI : 10.1016/j.ejphar.2005.11.014

M. Sergi, Y. Rassovsky, C. Widmark, C. Reist, S. Erhart et al., Social cognition in schizophrenia: Relationships with neurocognition and negative symptoms, Schizophrenia Research, vol.90, issue.1-3, pp.316-340, 2007.
DOI : 10.1016/j.schres.2006.09.028

H. Shimizu, Y. Iwayama, K. Yamada, T. Toyota, Y. Minabe et al., Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia, Schizophrenia Research, vol.84, issue.2-3, pp.244-52, 2006.
DOI : 10.1016/j.schres.2006.03.017

T. Shinoda, S. Taya, D. Tsuboi, T. Hikita, R. Matsuzawa et al., DISC1 Regulates Neurotrophin-Induced Axon Elongation via Interaction with Grb2, Journal of Neuroscience, vol.27, issue.1, pp.4-14, 2007.
DOI : 10.1523/JNEUROSCI.3825-06.2007

K. Talbot, D. Cho, W. Ong, M. Benson, L. Han et al., Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin, Human Molecular Genetics, vol.15, issue.20, pp.3041-54, 2006.
DOI : 10.1093/hmg/ddl246
URL : http://hmg.oxfordjournals.org/cgi/content/short/15/20/3041

S. Taya, T. Shinoda, D. Tsuboi, J. Asaki, K. Nagai et al., 3-3epsilon complex through kinesin-1, DISC1 regulates the transport of the NUDEL, pp.15-26, 2007.

J. Volavka, P. Czobor, B. Sheitman, J. Lindenmayer, L. Citrome et al., Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder, American Journal of Psychiatry, vol.159, issue.2, pp.255-62, 2002.
DOI : 10.1176/appi.ajp.159.2.255

R. Young, S. Batkai, M. Dukat, and R. Glennon, -tetrahydro-1,3-dioxolo 4,5-g isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00109100